FDA Clears Unicycive's Oxylanthanum Carbonate for Hyperphosphatemia

The U.S. Food and Drug Administration (FDA) has approved Unicycive Therapeutics' Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The decision, which comes ahead of the target action date, provides a significant therapeutic option for patients struggling to manage phosphate levels, a critical factor in reducing cardiovascular risk associated with advanced kidney disease. The approval is expected to strengthen the company's portfolio and address a long-standing need for more effective phosphate binders in the nephrology market.

Industry analysts anticipate that the drug will enter the market promptly, offering clinicians an alternative to existing therapies. The approval is based on clinical data demonstrating the drug's efficacy in lowering serum phosphorus levels, with a safety profile consistent with current standards of care. Unicycive is expected to outline its commercialization strategy and distribution plans in the coming weeks, marking a pivotal moment for the biotechnology firm.